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Abstract
Background: Cervical cancer is the leading cause of female cancer-related deaths in Tanzania. Vaccination against
human papillomavirus (HPV) offers a new opportunity to control this disease. This study aimed to estimate the
costs of a school-based HPV vaccination project in three districts in Mwanza Region (NCT ID: NCT01173900),
Tanzania and to model incremental scaled-up costs of a regional vaccination program.
Methods: We first conducted a top-down cost analysis of the vaccination project, comparing observed costs of
age-based (girls born in 1998) and class-based (class 6) vaccine delivery in a total of 134 primary schools. Based on
the observed project costs, we then modeled incremental costs of a scaled-up vaccination program for Mwanza
Region from the perspective of the Tanzanian government, assuming that HPV vaccines would be delivered
through the Expanded Programme on Immunization (EPI).
Results: Total economic project costs for delivering 3 doses of HPV vaccine to 4,211 girls were estimated at about
US$349,400 (including a vaccine price of US$5 per dose). Costs per fully-immunized girl were lower for class-based
delivery than for age-based delivery. Incremental economic scaled-up costs for class-based vaccination of 50,290
girls in Mwanza Region were estimated at US$1.3 million. Economic scaled-up costs per fully-immunized girl were
US$26.41, including HPV vaccine at US$5 per dose. Excluding vaccine costs, vaccine could be delivered at an
incremental economic cost of US$3.09 per dose and US$9.76 per fully-immunized girl. Financial scaled-up costs,
excluding costs of the vaccine and salaries of existing staff were estimated at US$1.73 per dose.
Conclusions: Project costs of class-based vaccination were found to be below those of age-based vaccination
because of more eligible girls being identified and higher vaccine uptake. We estimate that vaccine can be
delivered at costs that would make HPV vaccination a very cost-effective intervention. Potentially, integrating HPV
vaccine delivery with cost-effective school-based health interventions and a reduction of vaccine price below US$5
per dose would further reduce the costs per fully HPV-immunized girl.
Keywords: Africa, costs and cost analysis, economics papillomavirus vaccines, uterine cervical neoplasms
Background
Cervical cancer is the second most frequent cancer in
women worldwide [1]. More than 80% of cervical cancers
occur in developing countries [2]. In Tanzania, as in much
of sub-Saharan Africa, cervical cancer is the leading cause
of female cancer deaths [3,4]. Human papillomaviruses
(HPV) are the etiological agents of cervical cancers [5],
and vaccines against HPV (types 16 and 18) offer the
opportunity to prevent about 70% of cervical cancer cases
worldwide [6]. Many high-income countries have national
HPV vaccination programs [7], and Tanzania plans to
start a national HPV vaccination program in late 2012 [8].
Following the November 2011 decision of the Global Alli-
ance for Vaccines and Immunisations (GAVI) to move
towards funding HPV vaccines for eligible countries [9],
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HPV vaccination could become an option in many coun-
tries where HPV vaccines are currently unaffordable.
International studies have estimated that HPV vaccina-
tion of young girls would be cost effective in the 72
GAVI-eligible countries [10], and in Eastern Africa in
particular [11], if the costs per vaccinated girl were
between US$10 and US$25. However, preadolescent and
adolescent schoolgirls, the target group for HPV vaccines,
are not routinely included in most national immunization
programs in sub-Saharan Africa. The costs of delivering
HPV vaccines are therefore unknown [11]. To plan for
introducing HPV vaccines into national programs and to
estimate cost effectiveness, governments and researchers
need reliable estimates based on observed local costs.
This costing study was conducted as part of a project in
Mwanza Region, Tanzania, which measured the feasibility,
uptake, and acceptability of two alternative school-based
HPV vaccine delivery strategies using a cluster randomized
trial design (NCT ID: NCT01173900) [12]. It aimed to
analyze the observed costs of the school-based vaccination
project and to explore cost differences between delivering
vaccines to rural and urban schools and between the two
alternative delivery strategies. It also aimed to estimate
incremental costs of a scaled-up vaccination program for
Mwanza Region and to calculate the associated costs per
fully-immunized girl.
Methods
First, a top-down cost analysis of the school-based vacci-
nation project was conducted from the project’s perspec-
tive, using resource use and cost data collected alongside
the cluster randomized trial. Second, based on the
observed project costs, incremental costs of a scaled-up
vaccination program for Mwanza Region were modeled
from the perspective of the Tanzanian government, under
the assumption that HPV vaccines would be delivered
through the Expanded Programme on Immunization
(EPI).
Top-down analysis of project costs
Study setting and intervention
The HPV vaccination project compared vaccine coverage
in 134 primary schools randomly allocated to age-based
(girls born in 1998) and class-based (class 6 of primary
school in 2010) vaccine delivery in the two districts of
Mwanza City and part of neighboring Misungwi district in
northwest Tanzania. School-based vaccination was
selected for the study because it has the best chance of
achieving high coverage in Tanzania [12], where the gov-
ernment has a universal primary education policy and
more than 80% of girls attend primary school (87% in
urban regions, 80% in rural regions) [13]. In 2010, about
26% of the Tanzanian population were estimated to be
living in urban areas and urbanization was rapidly
progressing with an annual urban population growth rate
of 4.5% [14].
The project was carried out by the Mwanza Intervention
Trials Unit (MITU) of the National Institute for Medical
Research (NIMR), in collaboration with the London School
of Hygiene and Tropical Medicine (LSHTM). (Additional
file 1, Table S1 provides more details on the main activities
of the intervention.) Ethical approval was obtained from
the ethics committees of the Tanzanian Medical Research
Coordinating Committee and the London School of
Hygiene and Tropical Medicine. More details on consent
procedures and refusal rates are presented in Watson-
Jones et al. [12] and Remes et al. [15].
During the preparation phase, 242 schools were
mapped and the number of girls in each was documen-
ted. Subsequently, 134 schools (60 rural and 74 urban)
were randomly selected for vaccination, and then ran-
domly allocated to either age-based or class-based vaccine
delivery. Information about HPV vaccination was provided
through school, parent and community meetings, leaflet
and poster distribution, radio messages and community
drama troupes. Two 2-day training sessions were held to
train 84 health workers from 42 health facilities in cervical
cancer, HPV vaccination, cold-chain logistics and in man-
agement and reporting of adverse events.
The quadrivalent (HPV 6, 11, 16 and 18) vaccine (Merck
& Co.) was donated by Axios Healthcare Development,
Cleveland, Ohio, USA (GARDASIL® Access Programme).
The project covered costs of clearance and shipment of
vaccines from arrival in Dar es Salaam to Mwanza. Vac-
cines were stored at MITU in three refrigerators under the
supervision of a pharmacist. Between August 2010 and
July 2011, eligible girls were offered three doses of vaccine
during four vaccination rounds. On vaccination days, pro-
ject vehicles took MITU supervisory nurses, EPI-trained
nurses from health facilities that covered the selected
schools, vaccines, and necessary supplies to the schools
according to a prearranged timetable. After vaccination
days, girls who missed vaccination at schools were given
the opportunity to be vaccinated at health facilities during
a window period of 2 to 4 weeks. At the end of the win-
dow, remaining vaccines were returned to MITU because
of cold storage capacity constraints at the health facilities.
Materials used during vaccination were also returned
to MITU and incinerated. International and local MITU
staff were involved in administration, coordination and
supervision of the project. All activities and project
inputs related to research, including a proportion of the
preparation costs, were excluded from the cost analysis
(see Additional file 1, Table S1).
Data collection and analysis
Full financial and economic costs of running the project
in 2010 and the first two quarters in 2011 were estimated
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using adapted versions of established costing guidelines
[16,17]. Financial costs represent actual expenditures on
goods and services, while economic costs represent the
economic value of all resources used including costs of
goods and services that were not paid for by the project
(for example, vaccines donated by Axios Healthcare
Development).
Cost data were collected from the financial depart-
ments of the relevant institutions (MITU, NIMR, and
LSHTM) by a researcher (WQ) during two visits to
Mwanza in November 2010 and April 2011. Interviews
were conducted with all relevant project staff members,
as well as with regional and district EPI staff. Logbooks
of project cars were evaluated to determine distances tra-
velled. Vaccination of girls was observed by WQ during
the second round of vaccination at four schools to record
the time that nurses spent on vaccination activities at dif-
ferent types of school. During the third round of vaccina-
tion, MITU nurses recorded the time spent at schools
and travel times between MITU, health facilities and
schools for 40 schools. These data were complemented
by time data recorded in logbooks of project cars to esti-
mate the proportion of total time that MITU nurses
spent for procurement and vaccination for each type of
school (24% of total time for age-based urban, 22% for
age-based rural, 28% for class-based urban, and 26% for
class-based rural schools). In addition, vehicle logbooks
were used to determine the proportion of total km tra-
velled for delivering vaccines to rural and urban schools
(75% and 25% of total km, respectively).
All cost data were distributed into five broad categories:
(I) personnel, (II) other recurrent (including clinic con-
sumables, communication, and so on), (III) allowances,
(IV) transport, and (V) other capital costs for equipment.
Annual capital costs were estimated based on replacement
costs (for example, of comparable new vehicles or refrig-
erators) and assuming a life expectancy of 10 years for
vehicles and refrigerators, and 5 years for other electronic
equipment. Annual financial costs were calculated through
straight-line depreciation, while annual economic costs
were calculated using a 3% discount rate [18]. An estimate
of the average running cost per km of project cars (incl.
driver salary, fuel, insurance, repairs) was available from
the MITU financial department.
Costs of personnel were assigned to project activities
based on staff estimates. Time inputs from government
employees contributing to the project (that is, health
facility nurses, teachers, other EPI staff) were included
under economic costs. Other recurrent costs (for exam-
ple, vaccination materials and allowances) could be
directly attributed to the relevant activities based on
information provided in the project management
accounts. As vaccines were donated, financial costs
exclude costs of the vaccine. Economic costs assume a
price per dose of HPV vaccine of US$5 [19]. In some
cases, information from the principal investigator, MITU
staff, or detailed financial records of the accounting
department allowed assignment of costs. Transport costs
were allocated to project activities on the basis of the km
attributed to each project activity. Other capital costs for
equipment (for example, refrigerators, cold boxes) could
be directly attributed to relevant activities. Building costs
and overheads (for example, housekeeping, water, and
electricity except for refrigerators) were not considered.
Costs of training and social mobilization/information,
education, communication (IEC) were treated as start-
up costs and annuitized over 5 years. All cost data were
adjusted to the year 2011 using country-specific GDP
deflators [20], and were converted to US$ using average
2011 exchange rates [21].
Average financial and economic costs per fully-immu-
nized girl, that is, per girl who received three doses of
vaccine, were calculated by delivery strategy (age-based
or class-based) and school location (rural or urban) using
a two-step approach. First, total project costs for prepara-
tions, social mobilization/IEC, training, administration/
supervision, and for most cost elements of procurement
and vaccination, were assigned to schools by delivery
strategy and school location. Cold storage, recurrent
costs of procurement and vaccination, and waste man-
agement were allocated to schools on the basis of the
average number of doses delivered in each type of school.
Second, costs per school were divided by the average
number of fully-immunized girls per school. Table 1 pre-
sents the number of girls per school by delivery strategy
and school location, and compares these numbers to
those expected in a regional vaccination program (see
below).
Incremental costs of a scaled-up regional vaccination
program
A model was constructed in order to estimate the incre-
mental financial and economic costs of a scaled-up vacci-
nation program in Mwanza Region using an ingredients
approach. Reflecting the plans of the Tanzanian govern-
ment [8], the model estimates the additional costs of a
class-based delivery program targeting girls in class 4 of
primary school. Constructing the model involved two
steps: first, quantities of necessary resources were esti-
mated on the basis of experiences gathered during the
school-based vaccination project, taking into account
information from interviews with regional and district EPI
staff about service delivery within routine EPI programs,
statistics from the Ministry of Education and Vocational
Training (MOEVT) [22], and assumptions from a WHO
planning and costing tool for estimating costs of introdu-
cing HPV vaccines [23]. (Additional file 1, Table S2 pro-
vides an overview of the cost categories, inputs included,
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and sources of information.) Second, unit costs or prices
were assigned to the necessary inputs, using data from the
analysis of project costs, the EPI comprehensive multi-year
plan (CMYP) for Tanzania [8], and the WHO planning
and costing tool [23]. (A list of unit costs used in the
model can be obtained from the authors upon request.)
The model calculated total costs for Mwanza Region
and per fully-immunized girl by multiplying the assumed
resources per vaccinated school and girl by the estimated
unit costs. First, costs were estimated for a ‘base case sce-
nario’ using a number of ‘base case’ assumptions, which
are shown in Table 2. Subsequently, the influence of alter-
native assumptions for critical input parameters was tested
through sensitivity analyses. Again, financial costs exclude
the costs of HPV vaccine, while economic costs include
US$5 per dose.
Base case assumptions usually reflect findings from the
project cost analysis, interviews conducted with regional
and district EPI staff, a standard discount rate [18], num-
bers of girls from MOEVT statistics, and, for economic
costs, a price per dose of HPV vaccine of US$5 [19]. Low
cost assumptions assume only three vaccination rounds, a
longer life expectancy of capital equipment as well as of
sensitization and training, fewer additional or shorter dis-
tribution trips, higher coverage rates (as in existing EPI
programs [24]), lower unit costs for the shipment of vac-
cines to the regional EPI office, and they exclude the costs
of HPV vaccine. High cost assumptions use a discount
rate as published by the Bank of Tanzania [25], shorter
equipment life expectancies, and lower coverage rates.
Univariate and multivariate sensitivity analyses (SA)
were carried out using the ‘high cost’ and ‘low cost’
assumptions. For the univariate sensitivity analysis, one
model parameter was varied at a time with all other
parameters kept constant. For the multivariate SA, all
variables were simultaneously set to the ‘low cost’
assumptions or ‘high cost’ assumptions, respectively, in
order to generate the largest possible range of costs in
an analysis of extremes [26].
Results
Analysis of project costs
Total project costs
Total economic project costs for delivering 3 doses of
HPV vaccine to 4,211 girls in Mwanza City and Mis-
ungwi district (excluding research related activities) were
estimated to be US$349,000 (Figure 1). (Data for financial
and economic costs and for project costs by cost category
are available in Additional file 1, Table S3.) Administra-
tion/supervision accounted for 42% of total project costs.
Procurement accounted for 36% of total costs or US
$126,000, of which 53% were related to the costs of HPV
vaccines (assuming a price of US$5 per dose). Costs of
social mobilization/IEC and training, which were annui-
tized over 5 years, accounted for only US$12,200 (3.5%)
and US$6,400 (1.8%), respectively.
Project costs per fully-immunized girl
Figure 2 presents total economic project costs per fully-
immunized girl vaccinated with either age-based or
class-based delivery by location of school. The number
of vaccinated girls was much higher at class-based
schools than at age-based schools (Table 1). Total costs
per fully-immunized girl at urban schools were US$66
Table 1 Number of schools and girls (total and per school) by delivery strategy and school location in the Mwanza
Vaccination Project and in a scaled-up regional program
Class-based Age-based All schools
Urban Rural Total Urban Rural Total
Vaccination projecta
Vaccinated schools 36 30 66 34 30 64 130
Eligible girls (class 6, age 12)a 1,924 1,428 3,352 1,186 994 2,180 5,532
Fully-immunized girls
Total number 1,461 1,178 2,639 795 777 1,572 4,211
Average per school 40.6 39.3 40.0 23.4 25.9 24.6 32.4
Regional programb
Vaccinated schools 190 1,042 1,232 190 1,042 1,232 N/A
Eligible girls (class 4, age 10) 9,855 54,046 63,901 10,244 56,178 66,422 N/A
Fully-immunized girls
Total number (estimated)c 7,756 42,534 50,290 7,386 40,505 47,890 N/A
Average per school 40.8 40.8 40.8 38.9 38.9 38.9 N/A
aBased on [12], class-based is for class-year 6, age-based is for girls born in 1998.
bBased on [22], class-based is for class-year 4, which is a potential target group for the national human papillomavirus (HPV) vaccination program [8]. Age-based
is for 10-year-old girls, which is the age group most closely corresponding to class 4.
The number of fully-immunized girls assumes coverage rates as found in the Mwanza HPV Vaccination project for the class-based and age-based arms,
respectively. The two Mwanza City districts are urban, the six other districts of Mwanza Region are rural.
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for class-based delivery and US$100 for age-based deliv-
ery. Costs at rural schools were US$78 for class-based
delivery and US$107 for age-based delivery. Procure-
ment costs, including the costs of transporting vaccines
to schools, were considerably higher at rural schools
than at urban schools.
Costs of a scaled-up regional vaccination program
Total program costs
Table 3 shows the estimated incremental financial and
economic costs for a scaled-up vaccination program in
Mwanza Region. Incremental financial costs of delivering
3 doses of HPV vaccine through class-based delivery
(class 4 of primary school) to 50,290 girls were estimated
to be US$276,000, while economic costs (including vac-
cine costs at a price of US$5 per dose and the time inputs
of existing staff) were estimated to be US$1.3 million.
The costs of procurement, including the costs of vaccines
and supplies, shipment of vaccines to regional level,
transport to districts and distribution to health facilities,
account for the largest share of financial and economic
costs (46 and 73%, respectively). The costs of vaccination,
including the costs of nurses’ and teachers’ time as well
as allowances, account for 17% of economic costs.
Administration/supervision accounted for only 4.5% of
economic costs.
Costs per fully-immunized girl and sensitivity analysis
Under base case assumptions for input parameters, the
incremental economic scaled-up costs per fully-immunized
girl through class-based delivery in Mwanza Region,
including the cost of vaccine, were estimated at US$26.41.
(Data for urban and rural schools and a comparison with
project costs are presented in Additional file 1, Table S5
and Additional file 2, Figure S1.) The distribution of costs
across program elements and the relationship between
financial and economic costs mirrored the results pre-
sented in Table 3. Financial costs per fully-immunized girl,
excluding costs of the vaccine and salaries of existing staff,
were estimated at US$5.48 or US$1.73 per dose.
Univariate sensitivity analysis (SA) showed that exclud-
ing costs of HPV vaccines would reduce the costs per
fully-immunized girl to US$9.76 and a cost per dose given
of US$3.09. At 55% coverage for the third dose of HPV
vaccine, costs per fully-immunized girl would increase to
US$31.99 (Figure 3). Repeating sensitization/IEC and
Table 2 Selected input parameters for modeling of a scaled-up vaccination program in Mwanza Region
Base case Low cost High cost
General:
Number of vaccination rounds 4 3 Base case
Capital discount rate 3% 0% 8%
Life expectancy:
Vehicles 10 years 15 years 5 years
Refrigerators and cold rooms 10 years 15 years 5 years
Sensitization 5 years 7 years 1 year
Training 5 years 7 years 1 year
Cold storage:
Cold storage equipmenta Incremental volume Base case Incremental equipment
Procurement:
Additional vaccine distribution trips 3 1 4
Km per health facility per vaccination round, urban districts 43 30 50
Km per health facility per vaccination round, rural districts 73 50 90
Wastage rate (vaccines and materials) 5% 1% 10%
Vaccination:
Number of eligible girls per schoolb 52 60 40
Coverage ratesc for dose 1 86% 95% 75%
Coverage ratesc for dose 2 84% 90% 65%
Coverage ratesc for dose 3 79% 85% 55%
Girls immunized in health facilities (%) 4%
Unit costs:
Vaccine price US$5 US$0 Base case
Vaccine clearance and shipment to regional level (costs/dose) US$0.39 US$0.20 Base case
aIncremental volume refers to estimating the costs of the storage volume required for storing the estimated number of vaccine doses. Incremental equipment
refers to the necessary increase in cold storage equipment according to interviews with the district cold chain coordinators in Mwanza and Misungwi districts.
bThe number of eligible girls per school is varied by increasing/decreasing the total number of eligible girls in Mwanza Region.
cAs percentage of total cohort of eligible girls.
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training every year would lead to increased costs of US
$30.28, although some of these higher costs might be off-
set by an increase in coverage. The number of eligible girls
per school was also an important determinant of costs.
The impact of most other model input parameters on
costs was estimated to be small. Alternative assumptions
for life expectancy of vehicles and cold-storage equipment
did not have a strong influence on estimated costs. Even if
life expectancy of cold-storage equipment and vehicles
were only 5 years, costs would not considerably increase
(Figure 3). Multivariate SA showed that costs can increase
more than twice from the base case scenario to about US
$53, if all model parameters are set to the alternative high
cost assumptions.
Discussion
The World Health Organization recommends the inclusion
of HPV vaccination in national immunization programs for
girls 9 to 13 years old if (1) prevention of cervical cancer is
a public health priority, (2) the introduction is programma-
tically feasible, (3) sustained financing can be secured, and
(4) the cost effectiveness is considered [27]. However, with-
out detailed analyses of costs based on observed data col-
lected in countries, it is impossible to reliably estimate cost
effectiveness or to assess whether sustained financing will
be available for HPV vaccination. In sub-Saharan Africa,
where more than 1 million cancer cases could be averted
through HPV vaccination of 10 consecutive birth cohorts
of girls [28], empirical information about the delivery costs
of vaccines to young adolescent girls was unavailable until
very recently [11,29].
This is one of the first studies to report detailed
resource-use-based cost estimates for delivering HPV
vaccines to schoolgirls in sub-Saharan Africa. Using data
collected alongside a cluster randomized trial, our project
cost analysis demonstrated large differences in the costs of
delivering HPV vaccines to girls between age-based and
class-based delivery. In addition, modeled costs of a
scaled-up vaccination program for Mwanza Region in
Tanzania showed that three doses of HPV vaccine, when
excluding costs of the vaccine itself, could be delivered to
girls at an incremental economic cost of US$3.09 per dose
and about US$10 per fully-immunized girl. These esti-
mates are similar to the US$3.15 per dose that have been
reported by PATH and the national EPI program for a
school-based HPV vaccination program in Uganda [29],
but significantly higher than estimated for the costs of
delivering new childhood vaccines (also excluding vaccine
Figure 1 Contribution of project activities to total economic project costs (year 2011, US$).
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costs), such as pneumococcal or rotavirus vaccines in
Kenya (US$1.06) [30], Uganda (US$0.34) [31], or Malawi
(US$0.35) [32].
Our study has a number of limitations. First, despite our
high reliance on observed data, the analysis of project
costs was based on estimates and extrapolations for
certain inputs. Personnel time was allocated to different
activities of the intervention on the basis of staff inter-
views, which are a known source of uncertainty [33],
although prospective time sheets (from the third round of
vaccination), which are a better source of information,
were used to allocate costs between procurement and vac-
cination. Vehicle logbooks were used for the allocation of
transport costs but detailed records for the allocation
between rural and urban schools were only consistently
available for vaccination round three. However, these allo-
cations would not be expected to change over time since
the same schools were visited in each round. Furthermore,
project costs are not representative of how much it would
cost to deliver HPV vaccines within a national immuniza-
tion program: the project delivered HPV vaccines through
a vertical system specifically set up for the intervention.
Such systems imply high costs for administration/supervi-
sion, transport, and a dedicated cold chain. Procurement
costs in the project were particularly high for rural schools
as vehicles always had to travel from Mwanza City to the
rural district. In the scaled-up program, the difference in
procurement costs between urban and rural schools was
estimated to be much smaller as vaccines would be deliv-
ered from the district EPI office (see Additional file 2, Fig-
ure S1). In addition, salary costs of international staff
accounted for about 18% of project costs (Figure 1). If
they were replaced by their local equivalents, this would
result in a reduction in total project costs by almost 20%.
Second, our scaled-up cost estimates, which aimed to
overcome the problems of the project cost analysis by
adjusting the costs for administration/supervision, trans-
port and cold chain, have other limitations related to the
adopted ingredients approach for modeling of costs.
National level costs (such as administrative and supervi-
sion costs) were excluded, although these cost categories
can be important; and the ingredients approach may
underestimate inefficiencies. For example, for cold sto-
rage costs, the incremental costs of HPV vaccines were
calculated as the costs of the additional volume required
for storing the vaccines. However, if the introduction of
HPV vaccines required an increase in the number of
refrigerators or cold rooms, which would not be used
Figure 2 Project economic costs (year 2011 US$) per fully-immunized girl by school location and vaccination strategy. Data for the
Figure are available in Additional file 1, Table S4.
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during non-HPV-vaccination months, the incremental
costs would be much higher. For cold storage, such a sce-
nario was tested in the sensitivity analysis, which revealed
that increasing the number of refrigerators in Mwanza
Region to what district cold chain coordinators deemed
necessary for adding HPV vaccination would increase the
costs per fully-immunized girl by about 6%, that is, from
US$26.41 to US$27.90 (Figure 3).
Third, our model calculated scaled-up costs based on
experiences gathered over the course of the research pro-
ject and adjusted observed costs based on assumptions
derived from interviews with EPI staff in Mwanza City
and Misungwi District. The model assumed that similarly
high coverage rates would be achieved in a regional pro-
gram as in the research project; that distances travelled
from district stores to health facilities would be similar
for all rural districts as those in Misungwi District; and
that wastage rates of vaccines and materials would be
similar to those in existing EPI programs [24]. However,
the influence of alternative assumptions was tested in
sensitivity analyses (Figure 3), which showed that except
for the unlikely case of the full worst case scenario, esti-
mated costs would be relatively robust.
Despite these caveats, our research has major implica-
tions for policymakers and researchers. Firstly, in our pro-
ject cost analysis, we found that costs per fully-immunized
Table 3 Scaled-up class-based total costs of a human papillomavirus (HPV) vaccination program in Mwanza Region (in
2011 US$)*
Financial costs Economic costs
Program element US$ % US$ %
1. Social mobilization/IEC (annuitized):
1.1. Meetings (teachers, parents/pupils) 15,656 5.7% 23,504 1.8%
1.2. Campaign (radio, cultural troops) 3,254 1.2% 3,597 0.3%
1.3. Material development 20 0.0% 284 0.0%
Subtotal social mobilization/IEC 18,930 6.9% 27,385 2.1%
2. Training (annuitized):
2.1. District staff training 1,004 0.4% 2,472 0.2%
2.2. Health facility staff training 8,144 3.0% 21,954 1.7%
2.3. Material development 0 0.0% 524 0.0%
Subtotal training 9,148 3.3% 24,950 1.9%
3. Cold storage:
3.1. Regional level cold storage 111 0.0% 126 0.0%
3.2. District level cold storage 1,371 0.5% 1,596 0.1%
3.3. Health facility cold storage 13,536 4.9% 14,551 1.1%
Subtotal cold storage 15,018 5.4% 16,273 1.2%
4. Procurement:
4.1. Vaccines and supplies 19,162 6.9% 856,264 64.5%
4.2. Shipment to regional level 65,116 23.6% 65,116 4.9%
4.3. Transport to districts 2,923 1.1% 4,048 0.3%
4.4. Distribution to health facilities 39,603 14.4% 46,688 3.5%
Subtotal procurement 126,805 46.0% 972,115 73.2%
5. Vaccination:
5.1. School vaccination 62,992 22.8% 221,044 16.6%
5.2. Health facility vaccination 0 0.0% 5,247 0.4%
Subtotal vaccination 62,992 22.8% 226,291 17.0%
6. Waste management:
Subtotal waste management 1,020 0.4% 1,020 0.1%
7. Admin/supervision:
6.1. Regional level supervision 1,026 0.4% 2,047 0.2%
6.2. District level supervision 40,869 14.8% 57,955 4.4%
Subtotal admin/supervision 41,894 15.2% 60,002 4.5%
Overall total 275,807 100% 1,328,037 100%
aCosts are for delivering 3 doses of HPV vaccine through class-based delivery (year 4 of primary school) to 50,290 girls in Mwanza Region. Financial costs exclude
the costs of the vaccine itself, which will be donated to the Tanzanian government at least during the first years of the national vaccination program [8].
Economic costs include a vaccine price of US$5 per dose.
IEC = information, education, communication.
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schoolgirl of delivering three doses of HPV vaccines using
a class-based delivery strategy were about one-third below
those of using age-based delivery, although the costs per
school reached were not higher for age-based delivery (see
Additional file 3, Figure S2). The reason for the lower
costs per fully-immunized schoolgirl of class-based deliv-
ery in the project was the substantially higher number of
girls vaccinated at class-based schools due to more eligible
girls being identified and higher vaccine coverage (Table 1
and Watson-Jones et al. [12]). In a scaled-up regional pro-
gram, which is likely to target a different group of girls
(class 4 instead of class 6), the number of eligible girls per
school would be similar under age-based and class-based
delivery (Table 1). However, targeting a different age
group may have further cost and effectiveness implica-
tions, which need to be considered. About 99% of girls in
class 4 are in the target group for vaccination (between 9
and 13 years of age) [22] and are less likely to ever have
had sex before [13,34] than girls in class 6, where almost
20% are 13 years and older. However, as the full duration
of protection offered by HPV vaccines still remains uncer-
tain [35] (even if recent evidence has confirmed vaccine
efficacy of 8.4 years [36] and modeling results suggest 20
years protection [37]), a trade off might exist between tar-
geting girls early in life (prior to their sexual debut) and
ensuring that they are still protected later in life. Further-
more, earlier vaccination implies a requirement for earlier
booster doses, which may increase costs.
Secondly, we estimated scaled-up costs of US$26 per girl
fully immunized against HPV. Even when excluding vac-
cine costs (see Figure 3), US$10 is required for delivering
vaccines to schoolgirls. It is essential that these costs be
adequately budgeted during vaccine introduction, in
particular because a previous study found that system
costs (social mobilization/IEC, training, cold storage,
transport) were not covered by GAVI Alliance introduc-
tion grants during the introduction of DTwP-hepatitis
B-HiB vaccine in Ethiopia [38]. Furthermore, we found
that the costs of a school-based vaccination program,
when excluding costs of the vaccine, are mostly driven by
the costs of reaching schools, for social mobilization/IEC,
procurement and vaccination. Consequently, the marginal
costs per fully HPV-immunized girl and social mobiliza-
tion costs could potentially be reduced if HPV vaccines
were delivered together with other school-based health
interventions, such as tetanus toxoid (TT) vaccination,
vitamin A supplementation or deworming with antihel-
minthics [29,39] and/or reproductive health interventions.
In addition, if recent findings are confirmed that two-dose
HPV vaccine regimens may be effective for cervical cancer
prevention [40], costs per fully-immunized girl can be
expected to drop by about 30%.
Thirdly, our results should be incorporated into future
cost-effectiveness analyses of HPV vaccines in Eastern
Africa. Our model of a scaled-up regional HPV vaccina-
tion program estimated that costs per fully-immunized
girl would be about US$26 (see Figure 3), when including
a vaccine price of US$5 per dose [19]. Results of existing
cost-effectiveness studies [11,41] suggest that HPV vacci-
nation at US$25 per fully-immunized girl would be very
cost effective in all countries of Eastern Africa: at US$25
purchasing power parities (PPP) per vaccinated girl, the
costs per life-year saved (Campos et al. [11]) or per disabil-
ity adjusted life-year (DALY) averted (Kim et al. [41])
would be below the per capita income in these countries.
Of course, if HPV vaccine prices drop below US$5 and
Figure 3 Scaled-up class-based vaccination program: sensitivity analysis of incremental economic costs per fully-immunized girl (2011
US$).
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vaccines are delivered together with other school-based
health interventions (see above), cost effectiveness would
further increase. Currently, the GAVI decision to support
the introduction of HPV vaccines in developing countries
[9] and the donation offer to the Tanzanian government
of 2 million doses of HPV vaccine [8] present an unprece-
dented opportunity for the introduction of this life-saving
intervention.
Conclusions
The introduction of HPV vaccination in sub-Saharan
Africa offers a new opportunity for cervical cancer control.
Our cost estimates suggest that the vaccine can be deliv-
ered at costs that would make HPV vaccination a very
cost-effective intervention [11]. Potentially, delivering
HPV vaccines together with other cost-effective school-
based health interventions and a reduction of the vaccine
price below US$5 per dose would lead to lower costs and
higher cost effectiveness. Furthermore, if two-dose HPV
vaccine regimens were effective for cervical cancer preven-
tion [40], costs per fully-immunized girl would drop by
about 30%.
Additional material
Additional file 1: Additional tables. Table S1: activities performed
during the Mwanza human papillomavirus (HPV) vaccination project.
Table S2: program elements and included inputs for modeling of scaled-
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total financial and economic costs (year 2011 US$) for vaccination of
4,211 girls. Table S3b: project costs by cost category: total financial and
economic costs (year 2011 US$) for vaccination of 4,211 girls. Table S4:
data for Figure 2: project economic costs (year 2011 US$) per fully-
immunized girl by school location and vaccination strategy. Table S5:
data for Additional file 2, Figure S1: economic costs (year 2011 US$) per
fully-immunized girl in a scaled-up regional vaccination program and in
the Mwanza Vaccine Project by school location.
Additional file 2: Figure S1. Economic costs (year 2011 US$) per fully-
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Mwanza Vaccine Project (class-based delivery strategy) by school
location.
Additional file 3: Figure S2. Economic costs (year 2011 US$) per
vaccinated school in the Mwanza Vaccine Project by school location and
vaccination strategy.
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